Pharmaceutical Technology

MAY 8, 2023

Innovation S-curve for the pharmaceutical industry Anti-viral antigen-based compositions is a key innovation area in pharmaceuticals A viral antigen is a protein encoded by the viral genome that can be detected by a specific immunological response.

Antibody 147

Antibody Vaccine Vaccination Dermatology 147

Scienmag

FEBRUARY 18, 2021

Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development on February 18.

Gene Expression 72

Gene Expression Development Research Gene 72

XTalks

AUGUST 7, 2023

Verrica, a company specializing in dermatology therapeutics, has designed Ycanth to be delivered through a single-use applicator. It then activates enzymes known as neutral serine proteases, which are responsible for protein degradation. Ycanth (cantharidin) topical solution, developed by Verrica Pharmaceuticals Inc.,

FDA Approval 98

FDA Approval Dermatology Trials Clinical Trials 98

pharmaphorum

DECEMBER 15, 2020

Prevail is also developing PR004 for neurodegenerative diseases associated by the abnormal accumulation of alpha-synuclein protein in neurons, nerve fibres or glial cells. It is also working on therapies for Alzheimer’s and amyotrophic lateral sclerosis (ALS).

Gene Therapy 69

Gene Therapy Gene Dermatology Trials 69

Scienmag

MAY 28, 2021

MUSC Hollings Cancer Center researcher awarded Young Investigator Award to study the function of protein CDK6 in T-cells for melanoma therapy Credit: MUSC/Marquel Coaxum MUSC Hollings Cancer Center researcher Haizhen (Jen) Wang, Ph.D., recently was awarded a three-year $225,000 Young Investigator grant from the Melanoma Research Alliance.

Research 65

Research Scientist Protein Dermatology 65

The Pharma Data

JUNE 19, 2022

This occurs occurs over time as cancer patients are treated with drugs to enhance T-cell mediated immunity,” said Gavin Robertson, professor of pharmacology, pathology, dermatology and surgery, Penn State College of Medicine. Thus, the effect is better p53 pathway activation without the toxic effects seen with MDM inhibitors. .

Drugs 52

Drugs Protein Immune Response Scientist 52

pharmaphorum

SEPTEMBER 30, 2022

The Spanish drugmaker is paying $15 million upfront for rights to IL-2 mutant fusion protein (IL-2 mu-Fc) SIM0278 outside the Greater China region, with another $492 million pledged in development and commercial milestone payments if the drug works across multiple autoimmune indications. . Last year, Merck & Co paid $1.85

Licensing 52

Licensing Licensing Dermatology Drugs 52

pharmaphorum

DECEMBER 1, 2021

The French group said that ORI-001, a vaccine based on recombinant proteins from the Cutibacterium acnes (formerly Propionibacterium acnes ) bacterium that is often found in acne lesions, could be the first ever vaccine for the condition.

Vaccine 105

Vaccine Vaccination Development Hormones 105

Scienmag

NOVEMBER 16, 2020

Separately, this process may produce odors as bacteria present on the skin break down sweat proteins. Credit: Virginia Tech Sweating is a natural function of the human body, allowing a body to cool itself as sweat emerges from glands and evaporates.

Bacteria 52

Bacteria Protein Dermatology Engineer 52

Scienmag

APRIL 19, 2021

Protein “c-Jun” in the dendritic cell plays a major role in promoting psoriatic skin inflammation Psoriasis is a common inflammatory skin condition. The underlying genetic factors have not yet been sufficiently researched. The skin inflammation is usually triggered by external factors such as infections or stress.

Development 49

Development Genetics Protein Research 49

The Pharma Data

MARCH 27, 2022

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.

Dermatology 52

Dermatology Medicine Antibody Protein 52

The Pharma Data

AUGUST 16, 2021

In people with AD, the IL-13 protein—a central pathogenic mediator in the disease—is overexpressed, driving multiple aspects of AD pathophysiology by promoting T-helper type 2 (Th2) cell inflammation and resulting in skin barrier dysfunction, itch, infection and hard, thickened areas of skin. About Lilly in Dermatology.

Trials 40

Trials Dermatology Bioavailability Medicine 40

XTalks

SEPTEMBER 14, 2022

Used for both cosmetic and therapeutic cases, Botox is a US Food and Drug Administration (FDA)-approved injection of botulinum toxin, a neurotoxic protein that can effectively paralyze the facial muscles. One of the first options made available for such purposes was Botox from Allergan, brought to health practitioners’ offices in 1989.

Botox 98

Botox FDA Approval Cosmetics Clinical Trials 98

The Pharma Data

NOVEMBER 4, 2020

TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.

Licensing 40

Licensing Licensing Dermatology Production 40

pharmaphorum

JANUARY 6, 2023

ACELYRIN, Inc., a Los Angeles area-based, late-stage clinical biopharma, with additional operations in the San Francisco Bay area, has announced it is acquiring privately held ValenzaBio – which develops therapies for autoimmune and inflammatory diseases – in an all-stock transaction.

Trials 59

Trials Marketing Protein Antibody 59

The Pharma Data

JANUARY 24, 2021

It includes adults with confirmed COVID-19 on supplemental oxygen or mechanical ventilation with abnormal levels of at least two serum biomarkers, C reactive protein, D dimer, lactate dehydrogenase, or ferritin. It was run at nine hospitals in Brazil from May 8 to July 17, 2020.

Trials 52

Trials Allergies In-Vitro Antibody 52

The Pharma Data

JANUARY 13, 2021

Brilacidin is a first-in-class Host Defense Protein (HDP) mimetic with antiviral, anti-inflammatory and antibacterial properties. Food and Drug Administration (FDA) has designated as a Fast Track development program the investigation of Brilacidin as a potential treatment for COVID-19.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

JUNE 7, 2022

1-2 Lebrikizumab is a novel, monoclonal antibody (mAb) that binds to the interleukin-13 (IL-13) protein with high affinity to specifically prevent the formation of IL-13R?1/IL-4R? Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.

Trials 40

Trials Clinical Trials Clinical Trials Medicine 40

The Pharma Data

MAY 18, 2021

. “As the first biologic treatment for atopic dermatitis approved for this age group, DUPIXENT ® is a promising new option for treating children living with this chronic disease,” says Dr. Melinda Gooderham , Dermatologist and Medical Director at the SKiN Centre for Dermatology.

Production 40

Production Dermatology Medicine Clinical Trials 40

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 52

Production Dermatology Development Containment 52

Bioengineer

JULY 20, 2021

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. To learn more about Octagam 10% for the treatment of dermatomyositis, please click here. About the Octapharma Group.

FDA Approval 40

FDA Approval Clinical Trials Clinical Trials Trials 40

XTalks

AUGUST 2, 2023

Johnson & Johnson’s Top 5 Best-Selling Drugs of 2022: 1) Stelara (ustekinumab) Stelara is an immunosuppressant biologic therapy that blocks the IL-12 and IL-23 proteins that play a role in plaque psoriasis and Crohn’s disease. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells).

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

AUGUST 19, 2020

Nipocalimab gives Janssen the opportunity to reach significantly more patients by pursuing indications across many autoimmune diseases with substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Food and Drug Administration. An estimated 2.5

Production 40

Production Dermatology Development Containment 40

The Pharma Data

JUNE 28, 2021

. “Plaque psoriasis is a chronic autoimmune disease in which the immune system overproduces inflammatory proteins which results in red, scaly and thickened areas of skin,” said Dr. Jennifer Soung, dermatologist and Director of Clinical Research at Southern California Dermatology in Santa Ana, California.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

The Pharma Data

JULY 8, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation.

FDA Approval 52

FDA Approval Containment Trials Genome 52

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation.

HR 52

HR FDA Approval Containment Genome 52

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. 1-8 In addition, the extent of radiographic progression d was studied through two years. 1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S.

Medicine 52

Medicine Doctor Doctors Development 52

Delveinsight

AUGUST 13, 2020

SAR440340 History: Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation is thought to play an underlying role. Mastinib History: AB Science is majorly involved in the research, development and commercialization of protein kinase inhibitors (PKIs).

Antibody 40

Antibody Medicine Trials Development 40

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Initial data from LUMAKRAS in combination with a mitogen-activated protein kinase kinase (MEK) inhibitor and LUMAKRAS in combination with an oral EGFR inhibitor are planned to be submitted for presentation at a Q4 2021 medical conference.

Sales 52

Sales Production Antibody Development 52

The Pharma Data

SEPTEMBER 15, 2020

20vPnC showed a safety and tolerability profile that was similar to Prevnar 13 ® Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. Based on the acceptable safety profile and the favorable immune response data, including the 4th dose response data, Pfizer received Breakthrough Therapy Designation.

Gene Therapy 52

Gene Therapy Vaccine Vaccination Trials 52

The Pharma Data

AUGUST 11, 2020

We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early- to mid-stage development. Immune-Mediated Skin and Dermatologic Adverse Reactions.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

XTalks

DECEMBER 18, 2024

Cosibelimab-ipdl is a monoclonal antibody that inhibits PD-L1, a protein that tumors use to evade immune detection. While most cases are curable with surgical intervention, advanced cSCC, which either metastasizes or cannot be treated surgically, has a poor prognosis with limited therapeutic options.

FDA Approval 95

FDA Approval Antibody Immune Response Marketing 95

XTalks

JANUARY 2, 2025

Skyrizis targeted mechanism of action and long-lasting effectiveness have positioned it as a leading choice among modern biologics in dermatology.

Sales 85

Sales FDA Approval Drugs Marketing 85